You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

Article metrics

Article menu

Download PDFPDF

Thursday 06 October 2022 from 15:40 to 17:10
S11 immune system in SLE
S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

 

Online download statistics by month:

Online download statistics by month: September 2022 to March 2024

AbstractFullPdf
Sep 202266015
Oct 2022220033
Nov 2022848029
Dec 20226308
Jan 20235907
Feb 2023106016
Mar 20236808
Apr 20233008
May 20232204
Jun 20231201
Jul 20231702
Aug 20231201
Sep 20233203
Oct 20231802
Nov 20237104
Dec 20233804
Jan 20242201
Feb 20241902
Mar 20245207
Total17750155